A recent study published by Dove Medical Press investigates the real-world experiences of multiple myeloma (MM) patients who switched from intravenous (IV) to subcutaneous (SC) administration of daratumumab. The mixed-methods study, encompassing qualitative interviews and quantitative surveys across four European countries, highlights significant improvements in patient satisfaction, emotional well-being, and quality of life with the SC formulation.
Enhanced Patient Perception and Emotional Well-being
The research indicates a notable shift in patients' perceptions and feelings before and during daratumumab administration. Patients reported significantly lower levels of anxiety, stress, and nervousness before SC injections compared to IV infusions (p<0.001). Conversely, they felt more reassured, well-prepared, and relaxed with the SC route (p<0.001). These findings suggest that the SC formulation alleviates much of the emotional burden associated with the IV administration process.
Improved Quality of Life and Reduced Hospital Time
One of the most significant advantages of SC daratumumab is the reduced time spent in hospitals or clinics. The median time for SC injection was 1.5 hours, compared to 5.0 hours for IV infusion (p<0.001). This time-saving allows patients to resume their daily activities more quickly, with 84.1% reporting they had time for other activities immediately after SC injection versus only 29.2% after IV infusion (p<0.001).
Patient Satisfaction and Treatment Burden
Overall satisfaction with treatment was significantly higher for the SC injection, with 97.3% of patients satisfied compared to 89.4% for the IV infusion (p<0.001). Patients also found the SC treatment route more comfortable (91.2% vs 54.9% for IV, p<0.001) and less burdensome (22.1% vs 44.2% for IV, p<0.001).
Study Design and Methodology
The study involved a mixed-methods approach, beginning with qualitative interviews to explore patient experiences, perceptions, and attitudes towards switching from IV to SC daratumumab. The insights from these interviews informed the development of a quantitative survey, which was then administered to a larger group of patients (n=113) across France, Germany, Spain, and the United Kingdom.
Limitations
The authors acknowledge limitations, including potential response biases due to the self-reported nature of the survey and recall bias related to past experiences with IV daratumumab. The online approach in some countries may have introduced selection bias. However, the multi-country scope and mixed-methods design strengthen the findings.
Clinical Implications
The study's findings support the use of subcutaneous daratumumab as a preferable treatment option for multiple myeloma patients, offering improved patient experience, reduced treatment burden, and enhanced quality of life. The results underscore the importance of considering patient preferences in treatment decisions to optimize adherence and outcomes.
